about
Evolutionarily repurposed networks reveal the well-known antifungal drug thiabendazole to be a novel vascular disrupting agentDevelopment of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinasesTubulin-interactive natural products as anticancer agentsVascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma.Perfusion CT imaging of colorectal cancerEndothelial cell heterogeneityAntivascular ultrasound therapy extends survival of mice with implanted melanomasThrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation.Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.Potential role of vascular targeted therapy to combat against tumor.Antivascular therapy for epithelial ovarian cancer.Design, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-A4.A-ring dihalogenation increases the cellular activity of combretastatin-templated tetrazolesRapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform.Detection of tumor response to a vascular disrupting agent by hyperpolarized 13C magnetic resonance spectroscopy.An efficient synthetic strategy for obtaining 4-methoxy carbon isotope labeled combretastatin A-4 phosphate and other Z-combretastatins.Necrosis targeted combinational theragnostic approach using radioiodinated Sennidin A in rodent tumor models.Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent.A review on various targeted anticancer therapies.Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment.Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer modelsA dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumorsKML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model.A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels.A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessmentNitrotyrosine impairs angiogenesis and uncouples eNOS activity of pulmonary artery endothelial cells isolated from developing sheep lungs.Nanoparticle preconditioning for enhanced thermal therapies in cancerDesign and synthesis of 3,5-disubstituted boron-containing 1,2,4-oxadiazoles as potential combretastatin A-4 (CA-4) analogs.Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Cardiovascular toxicity profiles of vascular-disrupting agents.Current status of bevacizumab in advanced ovarian cancerDelta-projection imaging on contrast-enhanced ultrasound to quantify tumor microvasculature and perfusion.Hybrid alpha-bromoacryloylamido chalcones. Design, synthesis and biological evaluation.Synthesis and biological evaluation of Combretastatin A-4 derivatives containing a 3'-O-substituted carbonic ether moiety as potential antitumor agents.Drug resistance associated with antiangiogenesis therapy.Synthesis and in vitro cytotoxic activity of novel chalcone-like agents.AVE8062: a new combretastatin derivative vascular disrupting agent.Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapyThe development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
P2860
Q21145736-3AA79385-0E0E-4F0F-A141-2216EAE176C8Q24617675-D5D3272B-DE7B-4E2C-A07D-883980641D5FQ24650163-6ECD35A9-109F-4BDB-A425-1181E31FE109Q24651349-63221CEF-2049-4E9D-8585-ADE1CAC6A8A2Q27022129-68CB6E27-9B1F-4D02-8393-3E17D13578EEQ28740296-9552294F-9021-4126-8172-55F101E2BCD3Q30475723-72784A56-834B-41FD-B31E-C2B02C292862Q30482804-CFAB2A9A-C422-4BA7-BDCB-A4BAA22112A6Q30660860-2E209C62-1DC7-46FB-9845-3DF21277CF3FQ31024172-E83D8D68-BEF7-40CE-A9EE-0A49A933DE72Q33470615-06301C97-BA31-457B-8533-607D8F909157Q33583598-76FC14FA-DE3E-4903-9531-3B2C6D3449ACQ33606508-20C3153D-210A-4637-B75A-4EEDBE2D7224Q33630470-CEFA2C4F-B2A7-4291-832E-5F5648F6BD6EQ33691051-67252128-46AD-4E3B-A343-011A98CC2F25Q33772430-FF80B47C-9A95-4001-9FFA-04A449CD5D60Q33823154-C07141D3-0345-4ABE-8081-A953044C78A9Q33917524-0AF45384-6471-44F0-8D84-E6E5B7D802CCQ34122854-353F38EB-8696-4867-B35F-B3A7A576E98DQ34164735-1149350C-E62E-4C08-A703-20F934EA78BAQ34208140-2834008C-B47B-4164-8AC1-55A8ABBF81BBQ34430739-3A287AAB-C66E-49D2-94C2-25F255EE681CQ34546774-25537D74-BF7B-488D-8EB4-8C07757D699FQ34551903-429E5926-2EAE-4ADD-A8C7-B0D78A91C5A0Q34746019-E07325E8-4AF8-43BB-8903-217BAAD9E256Q34765364-AC13A2AA-7EE5-47A5-9E43-5C9FF9829D64Q34912263-1BBB2185-6014-477B-BCB4-98571F6E0206Q34987068-6CB5881C-F2BD-4C56-9E81-E9B95B1B0FFAQ34987894-1B4A5232-592E-4602-9151-430E3A1A521FQ35205410-F61BE24E-8F55-4871-86A7-F55A8D3A64C4Q35584746-26BBCCF8-8CD3-43F2-A4CD-E8D0DD27ED96Q37048186-9A7BE5E3-4596-4E68-83CD-AA17DA2126A9Q37101638-7457F487-7BD8-46D0-8ADF-10C5632571F0Q37270597-6D3DF473-AE82-4580-B637-4AAE3084BAEAQ37427582-71DB3A3F-E5F6-4DF8-8B99-7505F1D2558AQ37518288-89643D88-CD06-45C0-9568-D96C228A926EQ37540423-B6CEB128-1D95-4A04-88E5-1F3071051C58Q37598267-44079A49-115B-479E-90A0-B75A48B63D22Q37624281-0C2AC46A-DF14-4385-B459-CB8E6B8901FDQ37668618-03FF9D0A-948B-45CE-8D0C-D53670923318
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Vascular disrupting agents in clinical development
@ast
Vascular disrupting agents in clinical development
@en
type
label
Vascular disrupting agents in clinical development
@ast
Vascular disrupting agents in clinical development
@en
prefLabel
Vascular disrupting agents in clinical development
@ast
Vascular disrupting agents in clinical development
@en
P2860
P356
P1476
Vascular disrupting agents in clinical development
@en
P2093
F A L M Eskens
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603694
P407
P577
2007-03-20T00:00:00Z
2007-04-23T00:00:00Z
P5875
P6179
1035446044